CN114832831B - Composite nano enzyme synergistic catalytic fiber material and preparation method and application thereof - Google Patents
Composite nano enzyme synergistic catalytic fiber material and preparation method and application thereof Download PDFInfo
- Publication number
- CN114832831B CN114832831B CN202210420339.1A CN202210420339A CN114832831B CN 114832831 B CN114832831 B CN 114832831B CN 202210420339 A CN202210420339 A CN 202210420339A CN 114832831 B CN114832831 B CN 114832831B
- Authority
- CN
- China
- Prior art keywords
- enzyme
- fiber material
- spinning
- composite nano
- spinning solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002657 fibrous material Substances 0.000 title claims abstract description 67
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 66
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 66
- 239000002131 composite material Substances 0.000 title claims abstract description 65
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 56
- 230000003197 catalytic effect Effects 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000009987 spinning Methods 0.000 claims abstract description 83
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims abstract description 46
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 45
- 206010052428 Wound Diseases 0.000 claims abstract description 43
- 229920001577 copolymer Polymers 0.000 claims abstract description 39
- 239000004343 Calcium peroxide Substances 0.000 claims abstract description 34
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000019402 calcium peroxide Nutrition 0.000 claims abstract description 34
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000001035 drying Methods 0.000 claims abstract description 28
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 21
- 230000029663 wound healing Effects 0.000 claims abstract description 19
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 15
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 15
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 13
- 230000001684 chronic effect Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000008367 deionised water Substances 0.000 claims description 17
- 229910021641 deionized water Inorganic materials 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 15
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 10
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical group FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 7
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 7
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000012286 potassium permanganate Substances 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 7
- 229940038773 trisodium citrate Drugs 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 238000001523 electrospinning Methods 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 19
- 239000001301 oxygen Substances 0.000 abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 abstract description 19
- 230000035876 healing Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 82
- 239000000243 solution Substances 0.000 description 52
- 239000000835 fiber Substances 0.000 description 13
- 238000006555 catalytic reaction Methods 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000004366 Glucose oxidase Substances 0.000 description 5
- 108010015776 Glucose oxidase Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000019420 glucose oxidase Nutrition 0.000 description 5
- 229940116332 glucose oxidase Drugs 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000002789 catalaselike Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/76—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/84—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36 with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J23/889—Manganese, technetium or rhenium
- B01J23/8892—Manganese
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/002—Mixed oxides other than spinels, e.g. perovskite
-
- B01J35/40—
-
- B01J35/58—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/34—Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves ; Ionic sputtering; Flame or plasma spraying; Particle radiation
- B01J37/341—Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves ; Ionic sputtering; Flame or plasma spraying; Particle radiation making use of electric or magnetic fields, wave energy or particle radiation
- B01J37/342—Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves ; Ionic sputtering; Flame or plasma spraying; Particle radiation making use of electric or magnetic fields, wave energy or particle radiation of electric, magnetic or electromagnetic fields, e.g. for magnetic separation
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Abstract
The invention relates to a composite nano enzyme synergistic catalytic fiber material, a preparation method and application thereof, and belongs to the technical field of wound dressing. The composite nano enzyme synergistic catalytic fiber material is prepared by carrying out electrostatic spinning and drying on spinning solution A and spinning solution B; the spinning solution A consists of polylactic acid-glycolic acid copolymer, manganese dioxide nano-enzyme, calcium peroxide and spinning solvent, and the spinning solution B consists of polylactic acid-glycolic acid copolymer, ferroferric oxide nano-enzyme, calcium peroxide, benzoic acid and spinning solvent. The composite nano enzyme synergistic catalytic fiber material can efficiently and continuously generate oxygen and hydroxyl free radicals at the same time, so that the catalytic fiber material has the effects of oxygen supply and antibiosis, the wound healing, especially the healing speed of diabetes chronic wounds, is remarkably promoted, and the composite nano enzyme synergistic catalytic fiber material has the characteristics of convenience in use, simplicity in preparation and storage, and has the characteristic of absorbing seepage.
Description
Technical Field
The invention belongs to the technical field of wound dressing, and particularly relates to a composite nano enzyme synergistic catalysis fiber material, a preparation method and application thereof, in particular to application of the composite nano enzyme synergistic catalysis fiber material in preparing dressing for promoting wound healing, in particular to dressing for promoting chronic wound healing of diabetes.
Background
Diabetics are at risk of chronically unhealed wounds, even amputation, throughout life. Studies have shown that the primary cause of chronic wounds in diabetes is neovascular damage caused by hypoxia at the wound site. Under the condition of high content of glucose, the processes of hydroxylation, degradation, translation and the like of hypoxia-inducible factors at chronic wounds are seriously disturbed, so that wounds of diabetics cannot cope with ischemia conditions of soft tissues by up-regulating vascular endothelial growth factors, and further angiogenesis damages and slow healing of the wounds are caused. In addition to endogenous causes, delayed healing of wounds is also associated with bacterial infections. Compared with the common people, the wound of the diabetics contains higher sugar content, is more likely to cause invasion of bacteria, and the local edema and hypoxia environment of the wound is favorable for bacterial growth. Meanwhile, in the environment of high sugar, phagocytosis of white blood cells of diabetics is weakened, killing ability is reduced, bacteria are not easy to clear, and further infection area is enlarged. For less immune and resistant patients, once the wound is infected with bacteria, it is more difficult to heal completely. Therefore, the wound treatment of diabetics has difficulty in effectively controlling neovascular injury caused by hypoxia at the wound site and tissue infection caused by bacterial invasion.
In the prior art, the dressing for promoting the wound healing of diabetics is mainly hydrogel dressing, the principle of which is that the wound healing is promoted by improving the antibacterial capability of the wound, the problem of neovascular injury caused by hypoxia at the wound can not be solved, and the hydrogel has the defects of high storage condition, high clinical use difficulty and the like. An antibacterial hydrogel dressing for repairing diabetic wound surface and its preparation method (publication No. CN 1134766)45A) The dressing is firstly provided with TiO 2 /Ag 3 PO 4 Phosphate suspension, reconstituted polyacrylic acid (PAA) aqueous solution, calcium chloride aqueous solution and Glucose Oxidase (GO) x ) An aqueous solution; then mixing the polyacrylic acid aqueous solution, the calcium chloride aqueous solution and the glucose oxidase aqueous solution, and adding TiO under vigorous stirring 2 /Ag 3 PO 4 Phosphate suspension to obtain the antibacterial hydrogel dressing PAA@TiO 2 /Ag 3 PO 4 @ GOx. The dressing responds to phosphate radical in physiological environment to make Ca 2+ Is escaped, gel degradation is induced, and TiO is released 2 /Ag 3 PO 4 And GO x ，GO x The glucose in the wound surface is decomposed, and the local blood sugar concentration is reduced. TiO (titanium dioxide) 2 Catalytic H under illumination 2 O 2 Generates active oxygen to cooperate with Ag + Sterilizing, further reducing blood sugar concentration of wound surface, maintaining long-acting, high antibacterial activity and low cytotoxicity, and promoting healing of diabetic wound.
Disclosure of Invention
The invention provides a composite nano enzyme synergistic catalysis fiber material, a preparation method and application thereof, which can remarkably improve the healing speed of wounds, especially chronic wounds of diabetes, and has the characteristics of convenient use, simple preparation, simple preservation and liquid absorption.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows.
The composite nano enzyme synergistic catalytic fiber material is prepared by carrying out electrostatic spinning and drying on spinning solution A and spinning solution B;
the spinning solution A consists of polylactic acid-glycolic acid copolymer (PLGA), an internal admixture and a spinning solvent, wherein the internal admixture A consists of manganese dioxide nano-enzyme and calcium peroxide with the mass ratio of (1-9), the concentration of the polylactic acid-glycolic acid copolymer in the spinning solution A is 5-20wt%, and the mass ratio of the internal admixture to the polylactic acid-glycolic acid copolymer is 1:10;
the spinning solution B consists of a polylactic acid-glycolic acid copolymer, an inner blend B, benzoic acid and a spinning solvent, wherein the inner blend B consists of ferroferric oxide nano enzyme and calcium peroxide with the mass ratio of (1-9), the concentration of the polylactic acid-glycolic acid copolymer in the spinning solution B is 5-20wt%, the concentration of the benzoic acid is 0.5-2wt%, and the mass ratio of the inner blend B to the polylactic acid-glycolic acid copolymer is 1:10.
Preferably, in the spinning solution a and the spinning solution B, the concentration of the polylactic acid-glycolic acid copolymer is 10wt% respectively.
Preferably, the molecular weight of the polylactic acid-glycolic acid copolymer is 100000Da, and the molar ratio of lactic acid to glycolic acid=50:50.
Preferably, the spin solvent is hexafluoroisopropanol.
Preferably, in the spinning solution B, the mass ratio of the benzoic acid to the polylactic acid-glycolic acid copolymer is 1:5.
Preferably, the calcium peroxide is prepared by the following method: fully mixing calcium chloride and polyvinylpyrrolidone in ethanol, carrying out ultrasonic treatment for 0.5-2h, adding ammonia water, continuously stirring for 0.5-2h, then adding hydrogen peroxide at the speed of 0.05-0.2mL/min, continuously stirring until a light blue emulsion solution is obtained, washing with ethanol for multiple times, and drying at 60 ℃ to obtain monodisperse spheres, namely calcium peroxide;
the ratio of the calcium chloride to the polyvinylpyrrolidone to the ammonia water to the hydrogen peroxide is 0.1g:0.35g:1mL:0.6mL, and the concentration of the hydrogen peroxide and the concentration of the ammonia water are 1M and 0.8M respectively.
Preferably, the ferroferric oxide nano-enzyme is prepared by the following method: dissolving ferric chloride and trisodium citrate in ethylene glycol, adding anhydrous sodium acetate, stirring for 0.5-2h, reacting at 150-200 ℃ for 8-14h, cooling to room temperature, washing with ethanol for multiple times, washing with deionized water for multiple times, and drying at 60 ℃ to obtain a black product, namely the ferroferric oxide nano enzyme;
the proportion of the ferric chloride, the trisodium citrate and the anhydrous sodium acetate is 0.325g to 0.2g to 1.2g.
Preferably, the manganese dioxide nano-enzyme is prepared by the following method: dissolving potassium permanganate and concentrated hydrochloric acid in deionized water, continuously stirring for 0.5-2h, reacting for 2-24h at 120-200 ℃, cooling to room temperature, washing with ethanol for multiple times, washing with deionized water for multiple times, and drying at 60 ℃ to obtain manganese dioxide nano enzyme;
the proportion of the potassium permanganate and the concentrated hydrochloric acid is 0.225g to 0.5mL, and the concentration of the concentrated hydrochloric acid is 36-38%.
Preferably, the calcium peroxide is spherical and has a diameter of 70nm; the manganese dioxide nano enzyme is nano-tubular, and the cross section is 100nm; the ferroferric oxide nano enzyme is spherical and has the diameter of 250nm.
Preferably, the conditions of the electrospinning are as follows: the spinning voltage is 15-40kV, the pouring speed is 0.5-2mL/h, the receiving distance is 10-25cm, and the temperature in the spinning chamber is 15-30 ℃.
Preferably, the drying conditions are as follows: the temperature is 15-30 ℃, the humidity is 10-25%, and the time is 6-24h.
The invention also provides a preparation method of the composite nano enzyme synergistic catalytic fiber material, which comprises the following steps:
uniformly mixing calcium peroxide, manganese dioxide nano enzyme, polylactic acid-glycolic acid copolymer and a spinning solvent to obtain spinning solution A;
step two, uniformly mixing calcium peroxide, ferroferric oxide nano enzyme, benzoic acid, polylactic acid-glycolic acid copolymer and spinning solvent to obtain spinning solution B;
and thirdly, carrying out electrostatic spinning on the spinning solution A and the spinning solution B through two parallel spray heads, and drying the product to obtain the composite nano enzyme synergistic catalytic fiber material.
Preferably, in the first step and the second step, the mode of uniform mixing is uniform stirring and mixing, and the stirring time is 4-6h.
The invention also provides application of the composite nano enzyme synergistic catalytic fiber material in preparing a dressing for promoting wound healing.
Preferably, the wound is a diabetic chronic wound.
As shown in fig. 9 and 10, the principle of promoting wound healing by the synergistic catalysis of the fiber material by the composite nano enzyme of the invention is as follows: when the composite nano enzyme synergistic catalysis fiber material is placed on a wound surface, calcium peroxide in the composite nano enzyme synergistic catalysis fiber material undergoes hydrolysis reaction in the presence of wound exudates to generate hydrogen peroxide. Subsequently, two catalytic reactions will occur simultaneously at the wound site: one is manganese dioxide nano enzyme with catalase-like activity for catalyzing hydrogen peroxide to decompose to generate oxygen and water, wherein the oxygen can promote the formation of new blood vessels at the wound; in addition, the ferroferric oxide nano enzyme with peroxidase-like activity participates in a catalytic reaction under an acidic condition to catalyze hydrogen peroxide to decompose to generate hydroxyl free radicals, and the hydroxyl free radicals with strong oxidizing capability can play an effective bactericidal role.
Compared with the prior art, the invention has the beneficial effects that:
1. the composite nano enzyme synergistic catalytic fiber material utilizes the side-by-side double spinning nozzle to co-spin the spinning solution containing the peroxidase-like activity and the spinning solution containing the catalase-like activity, can efficiently and continuously produce oxygen and hydroxyl free radicals simultaneously, so that the catalytic fiber material has the effects of oxygen supply and antibiosis, namely, the catalytic fiber material remarkably improves the hypoxia microenvironment of the chronic wounds of diabetes, effectively stimulates the formation of new blood vessels, inhibits bacterial infection, prevents wound surface infection, accelerates wound healing, especially the healing of difficult-to-heal wounds of the diabetes, and has the characteristic of absorbing seepage.
2. The composite nano enzyme synergistic catalytic fiber material has the advantages of convenience in use, simplicity in preparation, simplicity in storage and the like, can play a role only by placing the composite nano enzyme synergistic catalytic fiber material at a wound, is convenient for a patient to use and reduces medical cost compared with the traditional inhalation of high-pressure oxygen and local gaseous oxygen therapy by means of large equipment, overcomes the defects of high storage condition, high clinical use difficulty and the like of hydrogel dressing, is convenient for the patient and medical staff to use, and lays a foundation for clinical application of the composite nano enzyme synergistic catalytic fiber material.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing the result of the oxygen generating ability of the hybrid fiber of example 2 of the present invention.
FIG. 2 is a graph showing the results of the ability of the hybrid fiber of example 3 of the present invention to generate hydroxyl radicals.
FIG. 3 is a scanning electron microscope image of the composite nano-enzyme co-catalytic fiber material of example 4 of the present invention; in the figure, a is a scanning electron microscope image, b is an element analysis image, c is an Fe element analysis image, d is an Mn element analysis image, e is a Ca element analysis image, and f is an O element analysis image.
FIG. 4 is a graph showing the oxygen generating capacity of the composite nano-enzyme synergistic catalytic fiber material of example 4 of the present invention.
FIG. 5 is a graph showing the results of the ability of the composite nano-enzyme of example 4 of the present invention to synergistically catalyze the generation of hydroxyl radicals in a fibrous material.
Fig. 6 is a graph showing the antibacterial test result of the composite nano-enzyme synergistic catalytic fiber material of example 4 of the present invention.
FIG. 7 is a graph showing the results of a composite nano-enzyme synergistic catalytic fiber material treated diabetic wound model of mice in example 4 of the present invention.
Fig. 8 is a graph showing the results of slice staining of a wound surface of a mouse treated with the composite nano-enzyme synergistic catalytic fiber material according to example 4 of the present invention.
Fig. 9 is a schematic diagram of the preparation and design of a composite nano-enzyme synergistic catalytic fiber material for promoting wound healing.
Fig. 10 is a schematic diagram of promoting wound healing by promoting wound healing with the composite nano-enzyme co-catalytic fiber material of the present invention.
Detailed Description
In order to further illustrate the invention, preferred embodiments of the invention are described below in connection with specific embodiments, but it should be understood that these descriptions are merely intended to further illustrate the features and advantages of the invention and are not limiting of the patent claims of the invention.
The composite nano enzyme synergistic catalytic fiber can remarkably improve the healing speed of chronic wounds of diabetes.
The composite nano enzyme synergistic catalytic fiber material is prepared by electrostatic spinning and drying of spinning solution A and spinning solution B;
the spinning solution A consists of polylactic acid-glycolic acid copolymer (PLGA, an internal blend A and a spinning solvent, wherein the internal blend A consists of manganese dioxide nano enzyme and calcium peroxide with the mass ratio of (1-9), the concentration of the polylactic acid-glycolic acid copolymer in the spinning solution A is 5-20wt%, and the mass ratio of the internal blend A to the polylactic acid-glycolic acid copolymer is 1:10;
the spinning solution B consists of polylactic acid-glycolic acid copolymer, an inner blend B, benzoic acid and a spinning solvent, wherein the inner blend B consists of ferroferric oxide nano enzyme and calcium peroxide with the mass ratio of (1-9), the concentration of the polylactic acid-glycolic acid copolymer in the spinning solution B is 5-20wt%, the concentration of the benzoic acid is 0.5-2wt%, and the mass ratio of the inner blend B to the polylactic acid-glycolic acid copolymer is 1:10.
In the above technical solution, the electrospinning is in the prior art, and the method for realizing the blending spinning of two spinning solutions in the prior art is not particularly limited, and the preferable conditions of the electrospinning are as follows: the spinning voltage is 15-40kV, the pouring speed is 0.5-2mL/h, the receiving distance is 10-25cm, and the temperature in the spinning chamber is 15-30 ℃. The spinning solvent is not particularly limited, and any spinning solvent commonly used in the art may be used, and hexafluoroisopropanol is preferable.
In the technical scheme, the drying conditions are as follows: the temperature is 15-30 ℃, the humidity is 10-25%, and the time is 6-24h.
In the above technical scheme, the mass ratio of benzoic acid to polylactic acid-glycolic acid copolymer is preferably 1:5.
In the above technical scheme, in the spinning solution A and the spinning solution B, the concentration of the polylactic acid-glycolic acid copolymer is preferably 10wt%. The polymerization degree of the polylactic acid-glycolic acid copolymer is not particularly limited, and it is preferable that the molecular weight of the polylactic acid-glycolic acid copolymer is 100000Da and the molar ratio of lactic acid to glycolic acid is 50:50. The particle sizes of the calcium peroxide, the manganese dioxide nano-enzyme and the ferroferric oxide nano-enzyme are not limited, and preferably, the calcium peroxide is spherical and has the diameter of 70nm; the manganese dioxide nano enzyme is nano-tubular, and the cross section is 100nm; the ferroferric oxide nano enzyme is spherical and has the diameter of 250nm. Polylactic acid-glycolic acid copolymer, calcium peroxide, manganese dioxide nanoenzyme, ferroferric oxide nanoenzyme are all of the prior art and can be obtained by means well known to those skilled in the art, such as commercial or laboratory preparation. The present invention provides several preparation methods, but is not limited thereto:
the calcium peroxide is prepared by the following method: fully mixing calcium chloride and polyvinylpyrrolidone in ethanol, carrying out ultrasonic treatment for 0.5-2h, adding ammonia water, continuously stirring for 0.5-2h, then adding hydrogen peroxide at the speed of 0.05-0.2mL/min, continuously stirring until a light blue emulsion solution is obtained, washing with ethanol for multiple times, and drying at 60 ℃ to obtain monodisperse spheres, namely calcium peroxide; wherein, the proportion of the calcium chloride, the polyvinylpyrrolidone, the ammonia water and the hydrogen peroxide is as follows: 0.1g:0.35g:1mL:0.6mL, the concentration of hydrogen peroxide and ammonia water is 1M and 0.8M respectively, ethanol is solvent, and the dosage is not particularly limited;
the ferroferric oxide nano enzyme is prepared by the following method: dissolving ferric chloride and trisodium citrate in ethylene glycol, adding anhydrous sodium acetate, stirring for 0.5-2h, reacting for 8-14h at 150-200 ℃, cooling to room temperature, washing with ethanol for multiple times, washing with deionized water for multiple times, and drying at 60 ℃ to obtain a black product, namely the ferroferric oxide nano enzyme; wherein, the proportion of ferric chloride, trisodium citrate and anhydrous sodium acetate is as follows: 0.325g, 0.2g, 1.2g, ethylene glycol as solvent, the dosage is not particularly limited;
the manganese dioxide nano-enzyme is prepared by the following steps: dissolving potassium permanganate and concentrated hydrochloric acid in deionized water, continuously stirring for 0.5-2h, reacting at 120-200 ℃ for 2-24h, cooling to room temperature, washing with ethanol for multiple times, washing with deionized water, and drying at 60 ℃ to obtain manganese dioxide nano-enzyme; wherein, the proportion of the potassium permanganate and the concentrated hydrochloric acid is 0.225g to 0.5mL, the concentration of the concentrated hydrochloric acid is 36-38%, deionized water is taken as a solvent, and the dosage is not particularly limited.
The invention also provides a preparation method of the composite nano enzyme synergistic catalytic fiber material, which comprises the following steps:
uniformly mixing calcium peroxide, manganese dioxide nano enzyme, polylactic acid-glycolic acid copolymer and a spinning solvent to obtain spinning solution A;
step two, uniformly mixing calcium peroxide, ferroferric oxide nano enzyme, benzoic acid, polylactic acid-glycolic acid copolymer and spinning solvent to obtain spinning solution B;
and thirdly, carrying out electrostatic spinning on the spinning solution A and the spinning solution B through two parallel spray heads, and drying the product to obtain the composite nano enzyme synergistic catalytic fiber material.
In the technical scheme, in the first step and the second step, the mode of uniform mixing is uniform stirring and mixing, and the stirring time is 4-6h.
The invention also provides application of the composite nano enzyme synergistic catalytic fiber material in preparing a dressing for promoting wound healing. Is especially suitable for promoting wound healing, especially chronic wound healing of diabetes. The specific using method comprises the following steps: the dressing is directly applied on the wound surface without special requirements.
In the following examples, various processes and methods, which are not described in detail, are conventional methods well known in the art. Materials, reagents, devices, instruments, equipment and the like used in the examples described below are commercially available unless otherwise specified.
The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art unless otherwise indicated.
The invention is further illustrated below with reference to examples.
Example 1
0.1g of calcium chloride and 0.35g of polyvinylpyrrolidone are fully mixed in 15mL of ethanol, ultrasonic treatment is carried out for 0.5h, 1mL of ammonia water (0.8M) is added into the solution, stirring is continued for 0.5h, then 0.6. 0.6mL hydrogen peroxide (1M) is added into the solution at the speed of 0.2mL/min, stirring is continued until a light blue emulsion solution is obtained, and finally ethanol is used for washing for 3 times, and drying is carried out at the temperature of 60 ℃, so that the product is monodisperse calcium peroxide spheres with the diameter of 70nm.
Dissolving 0.325g of ferric chloride and 0.2g of trisodium citrate in 20mL of ethylene glycol, adding 1.2g of anhydrous sodium acetate into the solution, stirring for 0.5h, adding the obtained mixed solution into a 50mL reaction kettle, continuously heating for 10h at 200 ℃, cooling to room temperature, washing with ethanol for 3 times, washing with deionized water for 3 times, and drying at 60 ℃ to obtain a black product which is spherical ferroferric oxide nano-enzyme with the diameter of 250nm.
Dissolving 0.225g of potassium permanganate and 0.5mL of concentrated hydrochloric acid in 20mL of deionized water, continuously stirring for 0.5, adding the obtained mixed solution into a 70mL reaction kettle, reacting for 12 hours at 140 ℃, cooling to room temperature, washing with ethanol for 3 times, washing with deionized water for 3 times, and drying at 60 ℃, wherein the obtained product is the nano tubular manganese dioxide nano enzyme with the cross section of 100 x 100nm.
Example 2
Step one, dissolving 0.1PLGA (molar ratio of lactic acid to glycolic acid=50:50, molecular weight of 100000 Da) in 0.89g hexafluoroisopropanol to obtain PLGA solution;
step two, mixing the inner admixture with the PLGA solution in the step one according to the mass ratio of the inner admixture to the PLGA of 1:10 to obtain spinning solution A;
wherein, the internal blend consists of manganese dioxide nano enzyme (prepared in example 1) and calcium peroxide (prepared in example 1) in mass ratio of 0:10, 1:9, 5:5 and 9:1;
step three, carrying out electrostatic spinning and drying on the spinning solution A to prepare hybrid fibers, wherein the electrostatic spinning conditions are as follows: the spinning voltage is 20kV, the pouring speed is 0.5mL/h, the receiving distance is 20cm, and the temperature in the spinning chamber is 25 ℃; the drying conditions are as follows: the temperature is 25 ℃, the humidity is 20 percent, and the time is 24 hours.
The four kinds of hybridized fibers prepared in example 2 were taken in 0.08g, placed in sample cells, respectively, 5mL of deionized water was added, and a dissolved oxygen tester was rapidly inserted, the system was sealed with a sealing film, and under magnetic stirring, the indication of the dissolved oxygen tester was recorded, and the result is shown in fig. 1. As can be seen from fig. 1, the oxygen generating capacity of the hybrid fiber is affected by the ratio of manganese dioxide nano-enzyme to calcium peroxide, and when the mass ratio of manganese dioxide nano-enzyme to calcium peroxide is 1:9, the oxygen generating rate of the hybrid fiber is the fastest and the oxygen generating amount is the highest.
Example 3
Step one, 0.1g of PLGA (molar ratio of lactic acid to glycolic acid=50:50, molecular weight 100000 Da) was dissolved in 0.89g of hexafluoroisopropanol to obtain a PLGA solution;
step two, mixing the inner admixture, the benzoic acid and the PLGA solution in the step one according to the mass ratio of the inner admixture to the PLGA of 1:10 and the mass ratio of the benzoic acid to the polylactic acid-glycolic acid copolymer of 1:5 to obtain a spinning solution B;
wherein, the internal blend B consists of ferroferric oxide (prepared in example 1) and calcium peroxide (prepared in example 1) with the mass ratio of 0:10, 1:9, 5:5 and 9:1;
step three, preparing hybrid fiber by electrostatic spinning and drying the spinning solution B, wherein the electrostatic spinning conditions are as follows: the spinning voltage is 20kV, the pouring speed is 0.5mL/h, the receiving distance is 20cm, and the temperature in the spinning chamber is 25 ℃; the drying conditions are as follows: the temperature is 25 ℃, the humidity is 20 percent, and the time is 24 hours.
The four kinds of hybridized fibers prepared in example 3 were taken in 0.01g each, placed in 5mL glass bottles, respectively, and then 200. Mu.L of TMB (10 mM) and 800. Mu.L of acetic acid buffer (pH=4.5) were added thereto, magnetically stirred for 20 minutes, and the absorption of the solution at 652nm was measured by an ultraviolet-visible absorption spectrometer, and the results are shown in FIG. 2. As can be seen from fig. 2, the hydroxyl radical generating capacity of the hybrid fiber is affected by the ratio of the ferroferric oxide nano enzyme to the calcium peroxide, and when the mass ratio of the ferroferric oxide nano enzyme to the calcium peroxide is 5:5, the absorption value of the solution at 652nm is highest, which indicates that the hybrid fiber has the strongest hydroxyl radical generating capacity.
Example 4
Uniformly mixing 9mg of calcium peroxide, 1mg of manganese dioxide nano-enzyme, 0.1g of polylactic acid-glycolic acid copolymer and 0.89g of hexafluoroisopropanol to obtain spinning solution A;
uniformly mixing 5mg of calcium peroxide, 5mg of ferroferric oxide nano-enzyme, 15mg of benzoic acid, 0.1g of polylactic acid-glycolic acid copolymer and 0.89g of hexafluoroisopropanol to obtain spinning solution B;
step three, carrying out electrostatic spinning on the spinning solution A and the spinning solution B through two parallel spray heads, and drying a product to obtain a composite nano enzyme synergistic catalytic fiber material; the conditions of the electrostatic spinning are as follows: the spinning voltage is 20kV, the filling speed is 0.5/h, the receiving distance is 20cm, and the temperature in the spinning chamber is 25 ℃; the drying conditions are as follows: the temperature is 25 ℃, the humidity is 20 percent, and the time is 24 hours.
4.1 scanning electron microscope observation was performed on the composite nano-enzyme synergistic catalytic fiber material of example 4.
Fig. 3 is a scanning electron microscope image of the composite nano-enzyme co-catalytic fiber material prepared in example 4, and as can be seen from fig. 3, the composite nano-enzyme co-catalytic fiber material has a uniform fiber structure, and in combination with various metals and oxygen elements shown in elemental analysis, the nano-material can be considered to be successfully encapsulated into the fiber, and has good dispersibility.
4.2 taking 0.16g of the composite nano enzyme synergistic catalytic fiber material prepared in the example 4, placing in a sample cell, adding 5mL of deionized water, rapidly inserting into a dissolved oxygen tester, sealing the system by using a sealing film, and recording the indication of the dissolved oxygen tester under magnetic stirring, wherein the result is shown in figure 4. As can be seen from fig. 4, the composite nano-enzyme synergistic catalytic fiber material prepared in example 4 has good oxygen production capacity.
4.3 the composite nano-enzyme synergistic catalytic fiber material prepared in example 4 was taken and placed in 5mL glass bottles, respectively, then 200 μl of TMB (10 mM) and 800 μl of acetic acid buffer (ph=4.5) were added, magnetically stirred for 20min, and the absorption of the solution at 652nm was measured using an ultraviolet-visible absorption spectrometer, and the results are shown in fig. 5. As can be seen from fig. 5, the composite nano-enzyme synergistic catalytic fiber material prepared in example 4 has good peroxidase activity.
4.4, the killing effect of the composite nano enzyme synergistic catalysis fiber material on staphylococcus aureus and escherichia coli is studied.
Preparing an LB culture medium: 2g of tryptone, 2g of sodium chloride and 1g of yeast extract are weighed, put into a conical flask, 200mL of deionized water is added, transferred into a sterilizing pot, sterilized for 20min and cooled to room temperature for standby.
Preparing a solid LB culture medium and paving a plate: 2g of tryptone, 2g of sodium chloride, 1g of yeast extract and 2.6g of agar are weighed into a conical flask, 200mL of deionized water is added, transferred into a sterilizing pot, and sterilized for 20min. Transferring the culture medium into a culture dish while the culture medium is hot, cooling the culture medium, and placing the cooled culture medium into a refrigerator for standby.
Coli (gram-negative bacteria) and staphylococcus aureus (gram-positive bacteria) will be used as models to study the antibacterial effect of the composite nano-enzyme synergistic catalytic fiber material. The individual strains were added to an Erlenmeyer flask containing LB medium and cultured at 37℃for 12h. Diluting the cultured bacterial liquid by 100 times with physiological saline, transferring 10 mu L of the bacterial liquid to be dripped into a 1 cm-1 cm composite nano enzyme synergistic catalytic fiber material, sealing and standing for 1h, repeatedly flushing with 990 mu L of physiological saline for several times, transferring 100 mu L of the bacterial liquid to LB solid medium, uniformly coating the bacterial liquid with a coater, culturing the coated solid medium at 37 ℃, and photographing and recording. The result shows that the composite nano enzyme synergistic catalytic fiber material has a strong bactericidal effect on escherichia coli and staphylococcus aureus, and is shown in figure 6.
4.5 research on repairing function of the composite nano enzyme synergistic catalytic fiber material on diabetic mouse wounds.
A mouse diabetes model is established, the back of a diabetic mouse is subjected to full-layer skin excision with the diameter of 8mm, and 30 mu L of a medicine containing 10 is added dropwise 8 -10 10 CFU mL -1 LB culture solution of staphylococcus aureus. And establishing a diabetic mouse wound infection model. Diabetic mice are divided into two groups, namely a control group and a composite nano enzyme synergistic catalytic fiber material group, and 6 groups are respectively arranged. The control group was not treated. The experimental group fixes the 1cm x 1cm composite nano enzyme synergistic catalytic fiber material on the wound surface, changes the composite nano enzyme synergistic catalytic fiber material every day, and observes and records the wound healing condition. The results show that the wound healing effect of the composite nano enzyme synergistic catalytic fiber material treated diabetic mice is obviously better than that of blank groups, as shown in fig. 7. Therefore, the composite nano enzyme synergistic catalytic fiber material related by the invention can be obviouslyPromoting healing of diabetic wound.
4.6 a mechanism for promoting wound repair of the diabetic mice by the synergistic catalysis of the fiber materials by the composite nano enzyme.
On day 13, the wound surface of 4.5 mice was removed, cut into slices, and HE and CD31 stained, and the results are shown in fig. 8. As can be seen from fig. 8, the mice treated with the composite nano-enzyme synergistic catalytic fiber material have better wound surface recovery, thicker epithelial tissues and more platelet endothelial cell adhesion molecules, which indicates that the composite nano-enzyme synergistic catalytic fiber material can accelerate wound healing by promoting the formation of epithelial tissues and new blood vessels.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (10)
1. The composite nano enzyme synergistic catalytic fiber material is characterized by being prepared by carrying out electrostatic spinning and drying on spinning solution A and spinning solution B;
the spinning solution A consists of a polylactic acid-glycolic acid copolymer, an internal blend A and a spinning solvent, wherein the internal blend A consists of manganese dioxide nano enzyme and calcium peroxide with the mass ratio of (1-9), the concentration of the polylactic acid-glycolic acid copolymer in the spinning solution A is 5-20wt%, and the mass ratio of the internal blend A to the polylactic acid-glycolic acid copolymer is 1:10;
the spinning solution B consists of a polylactic acid-glycolic acid copolymer, an inner blend B, benzoic acid and a spinning solvent, wherein the inner blend B consists of ferroferric oxide nano enzyme and calcium peroxide with the mass ratio of (1-9), the concentration of the polylactic acid-glycolic acid copolymer in the spinning solution B is 5-20wt%, the concentration of the benzoic acid is 0.5-2wt%, and the mass ratio of the inner blend B to the polylactic acid-glycolic acid copolymer is 1:10.
2. The composite nano-enzyme synergistic catalytic fiber material as claimed in claim 1, wherein,
in the spinning solution A and the spinning solution B, the concentration of the polylactic acid-glycolic acid copolymer is 10 weight percent respectively.
3. The composite nano-enzyme co-catalytic fiber material of claim 1, wherein the spinning solvent is hexafluoroisopropanol;
the molecular weight of the polylactic acid-glycolic acid copolymer is 100000Da, and the molar ratio of lactic acid to glycolic acid is 50:50.
4. The composite nano-enzyme synergistic catalytic fiber material as claimed in claim 1, wherein,
the calcium peroxide is prepared by the following method: fully mixing calcium chloride and polyvinylpyrrolidone in ethanol, carrying out ultrasonic treatment for 0.5-2h, adding ammonia water, continuously stirring for 0.5-2h, then adding hydrogen peroxide at the speed of 0.05-0.2mL/min, continuously stirring until a light blue emulsion solution is obtained, washing with ethanol for multiple times, and drying at 60 ℃ to obtain monodisperse spheres, namely calcium peroxide; the ratio of the calcium chloride to the polyvinylpyrrolidone to the ammonia water to the hydrogen peroxide is 0.1g to 0.35g to 1mL to 0.6mL, and the concentration of the hydrogen peroxide and the concentration of the ammonia water are 1M and 0.8M respectively;
the ferroferric oxide nano enzyme is prepared by the following method: dissolving ferric chloride and trisodium citrate in ethylene glycol, adding anhydrous sodium acetate, stirring for 0.5-2h, reacting for 8-14h at 150-200 ℃, cooling to room temperature, washing with ethanol for multiple times, washing with deionized water for multiple times, and drying at 60 ℃ to obtain a black product, namely the ferroferric oxide nano enzyme; the proportion of the ferric chloride, the trisodium citrate and the anhydrous sodium acetate is 0.325g to 0.2g to 1.2g;
the manganese dioxide nano-enzyme is prepared by the following method: dissolving potassium permanganate and concentrated hydrochloric acid in deionized water, continuously stirring for 0.5-2h, reacting for 2-24h at 120-200 ℃, cooling to room temperature, washing with ethanol for multiple times, washing with deionized water for multiple times, and drying at 60 ℃ to obtain the manganese dioxide nano-enzyme with controllable appearance, wherein the proportion of the potassium permanganate to the concentrated hydrochloric acid is 0.225g:0.5mL, and the concentration of the concentrated hydrochloric acid is 36-38%.
5. The composite nano-enzyme co-catalytic fiber material according to claim 1, wherein the conditions of electrospinning are: the spinning voltage is 15-40kV, the pouring speed is 0.5-2mL/h, the receiving distance is 10-25cm, and the temperature in the spinning chamber is 15-30 ℃.
6. The composite nano-enzyme co-catalytic fiber material of claim 1, wherein the drying conditions are: the temperature is 15-30 ℃, the humidity is 10-25%, and the time is 6-24h.
7. The method for preparing the composite nano-enzyme synergistic catalytic fiber material as claimed in any one of claims 1 to 6, which is characterized by comprising the following steps:
uniformly mixing calcium peroxide, manganese dioxide nano enzyme, polylactic acid-glycolic acid copolymer and a spinning solvent to obtain spinning solution A;
step two, uniformly mixing calcium peroxide, ferroferric oxide nano enzyme, benzoic acid, polylactic acid-glycolic acid copolymer and spinning solvent to obtain spinning solution B;
and thirdly, carrying out electrostatic spinning on the spinning solution A and the spinning solution B through two parallel spray heads, and drying the product to obtain the composite nano enzyme synergistic catalytic fiber material.
8. The method for preparing the composite nano-enzyme synergistic catalytic fiber material according to claim 7, wherein in the first step and the second step, the uniformly mixing mode is uniformly stirring and mixing, and the stirring time is 4-6h.
9. Use of a composite nano-enzyme co-catalytic fiber material according to any one of claims 1-6 for the preparation of a dressing for promoting wound healing.
10. The use of a composite nanoenzyme synergistic catalytic fiber material of claim 9 in the preparation of a dressing for promoting wound healing, wherein the wound is a diabetic chronic wound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210420339.1A CN114832831B (en) | 2022-04-21 | 2022-04-21 | Composite nano enzyme synergistic catalytic fiber material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210420339.1A CN114832831B (en) | 2022-04-21 | 2022-04-21 | Composite nano enzyme synergistic catalytic fiber material and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114832831A CN114832831A (en) | 2022-08-02 |
| CN114832831B true CN114832831B (en) | 2023-08-15 |
Family
ID=82566566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210420339.1A Active CN114832831B (en) | 2022-04-21 | 2022-04-21 | Composite nano enzyme synergistic catalytic fiber material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114832831B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090119943A (en) * | 2008-05-18 | 2009-11-23 | (주)고체산소테크 | Oxygen generating diaper and oxygen generating composition thereof |
| CN107117582A (en) * | 2016-02-24 | 2017-09-01 | 曹荣华 | It is a kind of locally quickly to produce the composition of oxygen |
| CN110384818A (en) * | 2019-07-29 | 2019-10-29 | 河南亚都实业有限公司 | A kind of alginate dressing |
| CN110772379A (en) * | 2019-11-01 | 2020-02-11 | 山东汉方制药有限公司 | Preparation method of composite nanofiber membrane loaded with nanoenzyme and wound surface application thereof |
| CN111588838A (en) * | 2020-05-29 | 2020-08-28 | 扬州大学 | Composition for inhibiting streptococcus mutans and application thereof |
| CN112376124A (en) * | 2020-11-20 | 2021-02-19 | 上海市第六人民医院 | Antibacterial dressing |
| CN112957457A (en) * | 2021-02-05 | 2021-06-15 | 山东大学 | Cascade enzyme-like nano system for promoting diabetic wound healing and preparation method and application thereof |
| WO2021122707A1 (en) * | 2019-12-19 | 2021-06-24 | Solvay Sa | Oxygen generating composition |
| KR20210111576A (en) * | 2020-03-03 | 2021-09-13 | 인하대학교 산학협력단 | Oxygen generating wound covering material and manufacturing method thereof |
| CN114163662A (en) * | 2021-12-16 | 2022-03-11 | 江南大学 | Nano enzyme functionalized hydrogel and preparation method thereof |
| CN114177347A (en) * | 2021-11-03 | 2022-03-15 | 暨南大学 | Antibacterial oxygen release functional gel dressing and preparation and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5756525B2 (en) * | 2010-12-20 | 2015-07-29 | ▲海▼洋王照明科技股▲ふん▼有限公司 | Manufacturing method and use of manganese dioxide nanorods |
-
2022
- 2022-04-21 CN CN202210420339.1A patent/CN114832831B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090119943A (en) * | 2008-05-18 | 2009-11-23 | (주)고체산소테크 | Oxygen generating diaper and oxygen generating composition thereof |
| CN107117582A (en) * | 2016-02-24 | 2017-09-01 | 曹荣华 | It is a kind of locally quickly to produce the composition of oxygen |
| CN110384818A (en) * | 2019-07-29 | 2019-10-29 | 河南亚都实业有限公司 | A kind of alginate dressing |
| CN110772379A (en) * | 2019-11-01 | 2020-02-11 | 山东汉方制药有限公司 | Preparation method of composite nanofiber membrane loaded with nanoenzyme and wound surface application thereof |
| WO2021122707A1 (en) * | 2019-12-19 | 2021-06-24 | Solvay Sa | Oxygen generating composition |
| KR20210111576A (en) * | 2020-03-03 | 2021-09-13 | 인하대학교 산학협력단 | Oxygen generating wound covering material and manufacturing method thereof |
| CN111588838A (en) * | 2020-05-29 | 2020-08-28 | 扬州大学 | Composition for inhibiting streptococcus mutans and application thereof |
| CN112376124A (en) * | 2020-11-20 | 2021-02-19 | 上海市第六人民医院 | Antibacterial dressing |
| CN112957457A (en) * | 2021-02-05 | 2021-06-15 | 山东大学 | Cascade enzyme-like nano system for promoting diabetic wound healing and preparation method and application thereof |
| CN114177347A (en) * | 2021-11-03 | 2022-03-15 | 暨南大学 | Antibacterial oxygen release functional gel dressing and preparation and application thereof |
| CN114163662A (en) * | 2021-12-16 | 2022-03-11 | 江南大学 | Nano enzyme functionalized hydrogel and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 组织工程用局部释氧材料的研究进展;裴大婷等;临床医学工程;第25卷;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114832831A (en) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113318272B (en) | Bone implantation material based on nano enzyme drug modification and preparation method and application thereof | |
| CN112957457B (en) | Cascade enzyme-like nano system for promoting diabetic wound healing and preparation method and application thereof | |
| CN113599506B (en) | Platinum nano enzyme/glucose oxidase @ hyaluronic acid composite antibacterial material and preparation and application thereof | |
| CN107185031A (en) | A kind of medical dressing with bioactivity and preparation method thereof | |
| CN110152055B (en) | Functional drug sustained-release medical dressing constructed by alginic acid aminated derivative/bacterial cellulose nanocrystalline composite gel | |
| CN114191562B (en) | Preparation method and application of double-enzyme-activity antibacterial material | |
| CN113262296A (en) | Nano reactor loaded with glucose oxidase and hemoglobin, and preparation method and application thereof | |
| CN113144270A (en) | Preparation method of photo-thermal sensitive composite bacterial cellulose antibacterial dressing | |
| CN109846854A (en) | A kind of reptile antibacterial peptide OH-CATH30 nanoparticle and nanofiber and its application | |
| Wang et al. | Mussel-inspired multifunctional hydrogel dressing with hemostasis, hypoglycemic, photothermal antibacterial properties on diabetic wounds | |
| Chen et al. | NIR regulated upconversion nanoparticles@ metal-organic framework composite hydrogel dressing with catalase-like performance and enhanced antibacterial efficacy for accelerating wound healing | |
| Fang et al. | Glucose oxidase loaded thermosensitive hydrogel as an antibacterial wound dressing | |
| CN114832831B (en) | Composite nano enzyme synergistic catalytic fiber material and preparation method and application thereof | |
| Zhang et al. | Hydrogen plasma treated-Ce-BTC nanorods enable enhanced antibacterial activity and soft tissue sealing ability | |
| Zhu et al. | A self-activated cascade nanoreactor based on Pd–Ru/GOx for bacterial infection treatment | |
| CN115584034A (en) | Injectable hydrogel material for wound repair and preparation method thereof | |
| CN113896242A (en) | Preparation method and application of oxygen vacancy molybdenum trioxide nanoparticles | |
| CN114796582A (en) | Preparation method of bacteriostatic gel containing graphene oxide | |
| CN113350376A (en) | Antibacterial metal nano enzyme OA-MnO2Preparation method and application of | |
| CN218552772U (en) | Dressing subsides for skin restoration | |
| CN114716817B (en) | Cerium dioxide nanorod hybridized multifunctional hydrogel, preparation method and application | |
| CN115634305B (en) | Multifunctional electrostatic spinning composite nanofiber material and preparation method and application thereof | |
| CN114106354B (en) | Nanocomposite capable of in-situ autocatalytic generation of hydrogen peroxide and sustained release of NO and free radicals, and preparation method and application thereof | |
| Montazer et al. | Preparation of a naturally driven cotton wound dressing via honey, Tragacanth and Sumac | |
| Tong et al. | Prussian blue nano-enzyme-assisted photodynamic therapy effectively eradicates MRSA infection in diabetic mouse skin wounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |